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Abstract Allergic contact dermatitis is an immune-medi-
ated antigen-specific skin reaction to an allergenic chemical
that corresponds to a delayed-type hypersensitivity response
(type IV reaction). Allergic contact dermatitis should be
suspected when skin lesions are localized to the site of pre-
vious applications of the culprit drug. Lesions appear after
re-exposure in susceptible persons, with delayed onset (more
than 24 h after exposure). The gold standard for diagnosis is
patch (epicutaneous) testing; identification and removal of
any potential causal agents is crucial. Diclofenac sodium 1%
topical gel contains active (diclofenac sodium) and inactive
ingredients. It is a widely used non-steroidal anti-inflam-
matory drug, known to cause allergic contact dermatitis, and
especially photoallergic contact reactions. We present four
cases of diclofenac-sodium-induced allergic contact der-
matitis, diagnosed based on clinical grounds: intensively
itchy eczematous lesions on the sites of drug application after
several days of treatment. No allergic history and no other
drug intake were reported by the patients. The application of
diclofenac sodium1% topical gelwas strictly forbidden in all
cases; potent topical steroids proved to be effective in all
cases within 2 weeks of therapy. Patch tests were performed
in all cases with European standard battery, with patients’
own diclofenac sodium 1% topical gels and with diclofenac
sodium 1% in petrolatum 3 weeks after completion of local
steroid therapy. Readings were done after 48 h (Day 2) and
72 h (Day 3) and proved to be positive only to patients’
diclofenac sodium 1% topical gel and diclofenac sodium 1%
in petrolatum. No sun exposure was allowed during the
testing, and any other treatments were forbidden.
Key Points
Patients and physicians must be aware of the risk of
cutaneous sensitization induced by topical
diclofenac, a drug that is also extensively used as
self-medication.
Discontinuation of topical application is the best
therapeutic approach and patients should be
informed about the allergic reaction to diclofenac
and counseled about avoiding the culprit medication.
Introduction
Contact dermatitis can be divided into irritant contact der-
matitis (ICD) and allergic contact dermatitis (ACD) [1].
ACD is an immune-mediated antigen-specific skin reaction
to an allergenic chemical that corresponds to a delayed-type
hypersensitivity response (type IV reaction). The gold
standard for diagnosis is patch (epicutaneous) testing [1].
This test has a sensitivity and specificity of between 70 and
80% [2]. Treatment of choice for ACD is topical corticos-
teroids, and a variety of symptomatic treatments can be used
to relieve the itching. However, identification and removal
of any potential causal agents is crucial [3]. Diclofenac is a
widely used non-steroidal anti-inflammatory drug (NSAID)
available in different formulations: tablets, ointments, plas-
ters, suppositories, and lipid nanoemulsions for parenteral
applications. Diclofenac sodium topical gel (DSTG)
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contains diclofenac sodium as the active ingredient, a white/
yellow crystalline powder soluble in ethanol, moderately
soluble in water and acetone, and partially insoluble in ether.
Diclofenac sodium (C14H10Cl2NNaO2) is the sodium salt
form of diclofenac, a benzene acetic acid derivate with
analgesic, antipyretic, and anti-inflammatory activity. It
inhibits cyclooxygenase (COX) non-selectively, reversibly,
and competitively with subsequent inhibition of the forma-
tion of prostaglandins, thromboxanes and prostacylin, which
are involved in mechanisms of pain, inflammation and fever.
DSTG also contains other inactive ingredients: benzyl
alcohol, hyaluronate sodium, polyethylene glycol (PEG),
sodium metilparaben, carbomer 940 (polyacrylic acid), tri-
ethanolamine, and purified water. The use of topical agents
containing PEG may cause ACD [4, 5]. DSTG is widely
used to relieve the pain and reduce the inflammation and
swelling of knees and joints of the hands; it is usually well
tolerated and rarely associated with minor local skin irrita-
tion. The use of topical NSAIDs provides pain relief without
associated severe systemic adverse events [6, 7]. The use of
topical diclofenac is associated with fewer side effects than
other topical NSAIDs and a lower rate of gastrointestinal
complications than oral NSAIDs [6, 8]. Still, diclofenac may
cause an increased risk of serious and fatal cardiovascular
thrombotic events and it is contraindicated for the treatment
of peri-operative pain in patients who have undergone
coronary artery bypass graft (CABG) surgery [6, 8]. Pho-
toallergic contact reactions have been reported with
diclofenac sodium 3% topical gel used as a topical treatment
for actinic keratoses [9]. Also, photoallergic contact der-




A62-year-old female patient diagnosedmany years agowith
rheumatoid arthritis, treated orallywithmethotrexate 10 mg/
week, applied DSTG 1% gel twice daily on her left wrist
under occlusive dressing. She noticed erythema with slight
edema on the site of drug application on the third day of use
(Fig. 1). She also complained of pruritus. The patient had no
history of atopy, no allergy history in the past, no other recent
drug intake apart from methotrexate. Discontinuation of
DSTG 1% gel was strongly advised. Potent steroid cream
(mometasone) was applied once daily for the following 2
weeks resulting in full recovery of the skin. Patient was
referred to the Allergy Department for patch testing 3 weeks
after the cessation of topical corticosteroid therapy. No sun
exposure was allowed during the testing, any other treat-
ments were forbidden. Patch test readings were done after 48
h (Day 2) and 72 h (Day 3) and were positive only to DSTG
1% (?/??) and 1% diclofenac sodium in petrolatum (?/
??); therefore, the ACD to diclofenac sodium was con-
firmed. The Naranjo Adverse Drug Reaction (ADR) Proba-
bility Scale was used and the score was calculated (patient’s
total score was 6, indicating a probable ADR).
Case 2
A 70-year-old female patient, suffering from right
gonarthrosis, was examined at our Dermatology Unit for
intense pruritus on inferior limbs, intense erythema and
desquamation on the right knee, and secondary identical
lesions on the left inferior limb. Dermatological exami-
nation revealed a large desquamating erythematous
lesion, well delineated, associated with slight edema and
scratch signs on the right knee. Scattered erythematous
papules coved by scales and diffuse erythema were
noticed on the left knee and left lower leg (Fig. 2). She
Fig. 1 Clinical presentation of Case 1
Fig. 2 Clinical presentation of Case 2
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described DSTG 1% gel application only on the right knee
for 5 consecutive days. First complaints were noticed on
the right knee, followed by occurrence of the same lesions
on the left knee and left lower limb. The presumed
mechanism of occurrence of the skin lesions on the other
leg is transfer of DSTG 1% gel from right knee to other
knee and id reaction. The application of DSTG was dis-
continued. The patient was treated with topical corticos-
teroid ointment (betamethasone) twice daily for 7 days
resulting in complete regression of lesions. Clinical
diagnosis of ACD to diclofenac sodium was confirmed by
positive patch. A patch test was performed 5 weeks later
and was positive only to the patient’s own DSTG 1% gel
(??/???) and 1% diclofenac sodium in petrolatum
(??/???). Readings were done at Day 2 and Day 3. The
patient’s Naranjo ADR probability score was calculated
(score was 6; ADR is probable).
Case 3
A healthy 51-year-old man was referred to the derma-
tology outpatient unit for intense erythema, edema, and
pruritus on the lumbosacral area (Fig. 3) that had been
noticed by the patient 4 days after self-application of
DSTG 1% several times per day for 4 consecutive days
for acute lumbago. He denied any drug intake and his
medical history was unremarkable. The application of the
culprit topical drug was stopped. Topical steroid (be-
tamethasone) proved to be effective after 2 weeks of
application. A patch test was performed 1 month later and
proved to be positive at Day 2 and Day 3 to DSTG 1% (?/
?) and 1% diclofenac sodium in petrolatum (?/?). The
Naranjo ADR Probability Scale was used (total score was
6; ADR is probable).
Case 4
A young 23-year-old man, on treatment with adalimumab
for psoriatic arthritis for the last 2 years, reported erythema,
slight infiltration, and pruritus in the lumbar region. He had
been applying DSTG 1% on the skin in the lumbosacral
region twice daily for 7 days prior to the consultation
(Fig. 4). Diclofenac was discontinued and local corticos-
teroid therapy (betamethasone) twice daily for 7 days was
introduced, resulting in complete resolution of skin lesions.
Three weeks later the ACD to diclofenac sodium was
confirmed by patch test to DSTG 1% (?/??) and 1%
diclofenac sodium in petrolatum (?/??). Readings were
done after 48 and 96 h. The patient’s Naranjo ADR prob-
ability score was 6, indicating a probable ADR.
Discussion
Our patients stated a clear history of the local adminis-
tration of the drug during their examination. ACD should
be suspected when skin lesions are localized to the site of
previous applications of the culprit drug. We recom-
mended drug-use cessation and treatment with potent
local corticosteroids. The gold standard for the diagnosis
of ACD (type IV hypersensitivity) is patch testing and
identification and removal of any potential causal agents
is of outmost importance [11–13]. The patients’ were
using DSTG 1% gel, containing diclofenac sodium and
other inactive ingredients including PEG. As PEG is a
well-known allergen that can induce ACD [4, 5], we had
to exclude that possibility by performing a patch test with
the European standard battery, patients’ own gel and
diclofenac sodium 1% in petrolatum. Readings were done
after 48 and 96 h for every patient following the European
Society of Contact Dermatitis guideline for diagnosticFig. 3 Clinical presentation of Case 3
Fig. 4 Clinical presentation of Case 4
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patch testing where (a) erythema, infiltration, and possibly
papules were considered weak positive reaction (?);
(b) erythema, infiltration, papules, and vesicles were
considered strong positive reaction (??); and (c) intense
erythema, infiltrate, and coalescing vesicles were con-
sidered extreme positive reaction (???) [11–13]. The
Naranjo ADR Probability Scale was used in all patients
and the ADR was assigned to a probability category
according to the score (score 0: ADR is doubtful, score
1–4: ADR is possible, score 5–8: ADR is probable, and
score C9: ADR is definite [14]. In all four cases, we
confirmed that the probable causative allergen in ACD
was diclofenac sodium, a chemical substance with
molecular weight 318.130 Da that is the active substance
in the patients’ gels used for pain relief.
Conclusion
Clear distinction must be made between allergic and
irritant reactions (Table 1) because of the different
therapeutic measures and clinical outcomes. The present
cases highlight ACD to topical diclofenac sodium diag-
nosed on clinical grounds and confirmed by patch test-
ing. DSTG can cause serious skin adverse events,
although application site reactions (application site der-
matitis) are the most frequent reason for treatment dis-
continuation [8]. DSTG, when suspected as allergen,
should be stopped immediately. The present cases of
ACD to diclofenac sodium were diagnosed by clinical
features and confirmed by patch testing. Discontinuation
of topical application is the best therapeutic approach
and patients should be informed about their allergic
reaction to diclofenac. Avoidance of the medication in
cases of a previously proven allergy to diclofenac is of
great importance.
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